ABSINTHIN

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C30H40O6
Molecular Weight	496.635
Optical Activity	UNSPECIFIED
Defined Stereocenters	14 / 14
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C[C@H]1[C@@H]2CC[C@](C)(O)[C@@H]3[C@H]4[C@H]5C=C(C)[C@@]6([C@H]7OC(=O)[C@@H](C)[C@@H]7CC[C@](C)(O)[C@H]56)[C@H]4C(C)=C3[C@H]2OC1=O

InChI

InChIKey=PZHWYURJZAPXAN-ILOFNVQHSA-N

InChI=1S/C30H40O6/c1-12-11-18-20-21(30(12)24(18)29(6,34)10-8-17-14(3)27(32)36-25(17)30)15(4)19-22(20)28(5,33)9-7-16-13(2)26(31)35-23(16)19/h11,13-14,16-18,20-25,33-34H,7-10H2,1-6H3/t13-,14-,16-,17-,18+,20-,21-,22-,23-,24-,25-,28-,29-,30+/m0/s1

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26495959 | http://foodb.ca/compounds/FDB014471

Absinthin is a triterpene, extracted from a Chinese herb, with anti-inflammatory properties.Absinthin is a naturally produced molecule from the plant Artemisia absinthium (Wormwood). It constitutes one of the most bitter chemical agents responsible for Absinthe's distinct taste. Absinthin attenuates LPS-induced ALI through MIP-1α-mediated inflammatory cell infiltration. Absinthin is a promising novel therapeutic candidate for the treatment of ALI.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Neutrophil collagenase 2 Target ID: O70138 Gene ID: 17394.0 Gene Symbol: Mmp8 Target Organism: Mus musculus (Mouse) Sources: https://www.ncbi.nlm.nih.gov/pubmed/26495959	Activator 1447

Conditions

Condition	Modality	Targets	Highest Phase	Product
Acute lung injury 20 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26495959	Primary		Preclinical	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Total synthesis of absinthin.	2005 Jan 12	15631427
Absinthe--a review.	2006	16891209
Women's health among the Chumash.	2006 Mar	16550233
Ultraviolet light absorption of an ophthalmic formulation with Aloe extracts.	2009 Sep	19831035

Patents

Sample Use Guides

In Vivo Use Guide

Mice were treated with various concentrations (20 mg/kg, 40 mg/kg, and 80mg/kg) of absinthin, and lipopolysaccharide (LPS) to induce ALI.

Route of Administration: Unknown

In Vitro Use Guide

RAW264.7 macrophages were treated with absinthin (either 10 ug/ml, 50 ug/ml, or 100 ug/ml) plus lipopolysaccharide (LPS) (1 ug/ml), or with LPS alone, for 24 h.

Name

Type

Language

ABSINTHIN

Common Name

English

NSC-407315

Preferred Name

English

ABSYNTHIN

Common Name

English

CHIEF BITTER PRINCIPLE OF ARTEMISIA ABSINTHIUM

Common Name

English

(+)-ABSINTHIN

Common Name

English

ABSINTHIN [MI]

Common Name

English

ABSINTHIIN

Common Name

English

Code System Code Type Description

PUBCHEM

442138